Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: Results of two phase II studies

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Javle, Milind M ^a   Shroff, Rachna T ^a   Xiong, Henry ^b   Varadhachary, Gauri A ^a   Fogelman, David ^a   Reddy, Shrikanth A ^a   Davis, Darren ^c   Zhang, Yujian ^c   Wolff, Robert A ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Center for Cancer and Blood Disorders   (United States)

^c ApoCell Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DIPHENHYDRAMINE; ERLOTINIB; EVEROLIMUS; GEMCITABINE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RAPAMYCIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; CANCER GROWTH; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; IMMUNOFLUORESCENCE TEST; INTERSTITIAL LUNG DISEASE; LASER SCANNING CYTOMETRY; LIPID BLOOD LEVEL; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIDE EFFECT; ADENOCARCINOMA; CANCER STAGING; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SIROLIMUS; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 77954478305     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-368     Document Type: Article

References (19)

1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
2. Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008, 113:2046-2052. 10.1002/cncr.23810, 18756532.
3. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 2004, 23:8571-8580. 10.1038/sj.onc.1207902, 15467756.
4. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 2004, 16:564-575. 10.1097/01.cco.0000143964.74936.d1, 15627018.
5. Cohen Y, Merhavi-Shoham E, Avraham-Lubin BC, Savetsky M, Frenkel S, Pe'er J, Goldenberg-Cohen N. PI3K/Akt pathway mutations in Retinoblastoma. Invest Ophthalmol Vis Sci 2009, 50:5054-6. 10.1167/iovs.09-3617, 19420344.
6. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966. 10.1200/JCO.2006.07.9525, 17452677.
7. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006, 5:2676-2684. 10.1158/1535-7163.MCT-06-0166, 17121914.
8. Papadimitrakopoulou V, Blumenschein GR, Leighl NB, Bennouna J, Soria JC, Burris HA, Dimitrijevic S, Kunz T, Di Scala L, Johnson BE. A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase 1 results. ASCO Meeting Abstracts 2008, 26:8051.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
10. Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ. Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res 2005, 11:678-689. 10.1158/1078-0432.CCR-04-1655, 15701856.
11. Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly M, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 2004, 10:33-42. 10.1158/1078-0432.CCR-0736-3, 14734449.
12. Thall PF, Simon R. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Control Clin Trials 1994, 15:463-481. 10.1016/0197-2456(94)90004-3, 7851108.
13. Rothenberg ML, Benedetti JK, Macdonald JS, Seay TE, Neubauer MA, George CS, Tanaka MS, Giguere JK, Pruitt BT, Abbruzzese JL. Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. Ann Oncol 2002, 13:1576-1582. 10.1093/annonc/mdf274, 12377645.
14. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610. 10.1200/JCO.2007.14.5482, 18332469.
15. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, Enzinger PC, Allen B, Clark JW, Ryan DP, Fuchs CS. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009, 27:193-198. 10.1200/JCO.2008.18.9514, 2645085, 19047305.
16. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SA. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 2005, 331:295-302. 10.1016/j.bbrc.2005.03.166, 15845392.
17. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940. 10.1038/sj.onc.1209990, 17001314.
18. Li J, DeFea K, Roth RA. Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. J Biol Chem 1999, 274:9351-9356. 10.1074/jbc.274.14.9351, 10092613.
19. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008, 68:8322-8332. 10.1158/0008-5472.CAN-07-6720, 18922904.